drugset / Trial / NCT03493217
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
NaSingle-groupOpen-labelTreatment
Summary
The phase I/II clinical study is to investigate the safety, tolerability and efficacy of ICP-022 in R/R CLL/SLL patients.
Timeline
- Start
- 2018-04-17
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | — | — |